A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)

By afschroeder • July 9, 2026

Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan X, Bamias A. A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma). ESMO Open. 2026 Jul 8;11(8):108303. doi: 10.1016/j.esmoop.2026.108303. Epub ahead of print. PMID: 42418909.

Tags: Atezolizumab, Hematology/Oncology, locally advanced or metastatic, MORPHEUS, prior platinum, Publications, Sacituzumab govitecan, urothelial carcinoma

Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity

Heskett MB, Vouzas AE, Johnstone B, Freese KP, Yates PA, Copenhaver PF, Spellman PT, Gilbert DM, Thayer MJ. Autosomal allelic inactivation at loci with variable[...]

The Association Between Healthcare Provider Trust and Healthcare Avoidance: Findings From a HIV Mixed Serostatus Cohort Study

Singleton M, Plankey M, Bowleg L, Brock JB, Haberlen S, Jamieson BD, Kempf MC, Konkle-Parker DJ, Kwait J, Martinson J, Mimiaga MJ, Ramirez CM, Stosor[...]

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, Žučenka A, Marvin-Peek J,[...]